Buy/Sell: Wall Street’s top 10 stock calls this week

What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street’s best analysts during the week of October 20-24. 

Find all top-rated stocks by the best-rated analysts on TipRanks.

Top 5 Buy Calls:

1. Loop upgrades Apple on “material upside” to iPhone estimates

Loop Capital upgraded Apple (AAPL) to Buy from Hold with a price target of $315, up from $226. Loop’s supply chain checks indicate iPhone shipments will expand through 2027 amid refresh and design cycles, the analyst tells investors in a research note. The firm sees “material upside” to consensus iPhone estimates through 2027. It believes Apple could be starting three consecutive record iPhone shipment years.

2. Amazon resumed with an Overweight at KeyBanc

KeyBanc resumed coverage of Amazon.com (AMZN) with an Overweight rating and $300 price target. Advertising is fueling gains in the company’s retail business, which provides a path forward for grocery becoming more material over the medium term, the firm tells investors in a research note. Investors have also become too pessimistic on the Cloud business, and the firm sees potential for improving growth into 2026.

3. Block initiated with a Buy at Citi

Citi initiated coverage of Block (XYZ) with a Buy rating and $105 price target. Block has turned the corner and is focused on accelerating growth, the firm tells investors in a research note. The upcoming Investor Day could give color for sustainable gross profit growth and modestly increasing the adjusted operating margins over the mid-term, Citi says.

Block initiated with an Overweight at Wells Fargo

Wells Fargo initiated coverage of Block with an Overweight rating and $91 price target. The firm, which started coverage on 20 stocks in the Payments, Processors & IT Services sector, says the Payments space has suffered from rotation to AI-centric stocks, as well as multiple instances of subpar execution by various companies, but Citi thinks “too many stocks have been painted with the same brush.” The Payments sector has “been a minefield for investors,” but the firm sees some “particularly attractive opportunities,” the firm added.

4. eBay upgraded to Outperform at Citizens JMP 

Citizens JMP upgraded eBay (EBAY) to Outperform from Market Perform with a $115 price target. The firm believes the company’s product initiatives are creating a “significantly better consumer experience” in its focus categories that can drive mid-single-digit merchandise volume growth in 2026. eBay is seeing a greater share of listings and reinforcing category flywheels, Citizens JMP tells investors in a research note. In addition, the firm thinks eBay’s core marketplace can remain the driver of this business, with artificial intelligence improving product discovery and ease of listings.

5. Capri Holdings upgraded to Outperform at Raymond James 

Raymond James upgraded Capri Holdings (CPRI) to Outperform from Market Perform with a $25 price target. Capri appears well-positioned for a turnaround following several challenging years, supported by improving demand signals, conservative FY26 guidance, and upside potential to FY27 estimates, the firm tells investors in a research note. Channel checks indicate sequential improvement, and stronger revenue growth and margin expansion could drive FY27 EPS meaningfully above current consensus, Raymond says.

Top 5 Sell Calls:

1. Rivian downgraded to Underperform at Mizuho

Mizuho downgraded Rivian (RIVN) to Underperform from Neutral with a price target of $10, down from $14. The firm cites slowing electric vehicle demand as Inflation Reduction Act credits expire for the downgrade. Mizuho sees headwinds in 2026 for Rivian due to with softer auto sales in North America and China risks. It cut Rivian’s 2026 deliveries forecast to 60,000 units from 68,000, below the consensus of 72,000.

2. Molina Healthcare downgraded to Underweight at Barclays 

Barclays downgraded Molina Healthcare (MOH) to Underweight from Equal Weight with a price target of $144, down from $185. The firm thinks the company’s preliminary 2026 earnings per share outlook of $14 is “too optimistic,” assuming its Medicaid medical loss ratio will be flat year-over-year. Despite Molina’s “disappointing” Q3 results and corresponding stock selloff, there remains downside risk to forward estimates, Barclays tells investors in a research note. The firm views the company’s building Medicaid pressure in the second half of 2025 as a “clear negative development” for 2026.

3. Progressive downgraded to Underweight at Morgan Stanley

Morgan Stanley downgraded Progressive (PGR) to Underweight from Equal Weight with a price target of $214, down from $265. The firm finds Progressive’s bull case less visible when stripping out Florida. Progressive is entering into a softer part of the pricing cycle, which is likely to compress valuation multiples further, the analyst tells investors in a research note. Morgan Stanley believes the cyclical nature of the business implies earnings declines in 2026 and 2027.

4. Cleveland-Cliffs downgraded to Underweight at Wells Fargo 

Wells Fargo downgraded Cleveland-Cliffs (CLF) to Underweight from Equal Weight with an unchanged price target of $11. The firm views the stock’s 22% rally on Monday as “excess exuberance.” The rally is an overreaction to a memorandum of understanding with a foreign steel mill and potential rare earth deposits, Wells tells investors in a research note. The firm considers Cleveland-Cliffs a beneficiary of a U.S. spot sheet price rebound into year end, but thinks the shares now more than reflect a better 2026.

5. BNP Paribas Exane downgrades NuScale Power to Underperform on ENTRA1 economics

BNP Paribas Exane downgraded NuScale Power (SMR) to Underperform from Neutral with a price target of $25, down from $41. On the firm’s estimate of about 4 GW of cumulative shipments by 20240, it estimates NuScale will pay ENTRA1 over $6B over the next 15 years under their milestone agreement, notes BNP Paribas, which says the ENTRA1 economics “fundamentally change how SMR must be valued.”